Abstract: An electromagnetic valve and an air conditioning system are provided. The electromagnetic valve includes a valve bonnet and a valve seat. The valve bonnet includes a large-diameter section and a small-diameter section, the small-diameter section extends into a mounting groove and is affixed to a groove wall of the mounting groove, and the large-diameter section abuts against the valve seat. A first sealing surface is formed by the large-diameter section abuts against the valve seat, and a second sealing surface is formed by the small-diameter section is affixed to the groove wall of the mounting groove. The valve bonnet and the valve seat are connected in a hard sealing connection manner at the first sealing surface, and the valve bonnet and the valve seat are connected in a soft sealing connection manner at the second sealing surface.

Abstract: Chitosan-nucleic acid polyplex compositions containing a reversibly bound polymer coat comprising linear block copolymers with a polyanionic anchor region and at least one polyethylene glycol tail region are described herein. In some cases, the compositions exhibit improved stability and/or mucosal diffusion as compared to uncoated particles. In some cases, the reversibly bound polymer coat does not interfere with, or enhances, transfection of target cells or tissues as compared to uncoated particles.

Abstract: The present disclosure relates to methods and compositions comprising derivatized-chitosan polyplexes reversibly coated with a polyanion-containing block co-polymer for the localized expression of IL-12 in mucosal tissues, preferably in combination with an IFN-1 activator/inducer, for use in cancer immunotherapy.

Abstract: Provided are chimeric receptors targeting NKG2D, and multispecific chimeric receptors comprising an NKG2D domain and a second antigen binding domain such as an IL-3 domain. Also provided are dual chimeric receptor systems comprising a first chimeric receptor comprising an NKG2D domain, and a second chimeric receptor comprising a second antigen binding domain such as an IL-3 domain. Further provided are engineered immune effector cells (such as T cells), pharmaceutical compositions, kits and methods of treating cancer.

Abstract: A process for preparing a zeolitic material, comprising (i) preparing a mixture comprising the at least one silicon containing precursor compound from which the zeolitic framework is formed, at least one pore forming agent, and at least one polymer which has an essentially spheroidal geometry in the mixture; (ii) crystallizing the zeolitic material from the mixture obtained in (i) to obtain the crystallized zeolitic material in its mother liquor.

Abstract: A process for preparing a zeolitic material, comprising (i) preparing a mixture comprising the at least one silicon containing precursor compound from which the zeolitic framework is formed, at least one pore forming agent, and at least one polymer which has an essentially spheroidal geometry in the mixture; (ii) crystallizing the zeolitic material from the mixture obtained in (i) to obtain the crystallized zeolitic material in its mother liquor.

Abstract: A process for preparing a zeolitic material, comprising (i) preparing a mixture comprising the at least one silicon containing precursor compound from which the zeolitic framework is formed, at least one pore forming agent, and at least one polymer which has an essentially spheroidal geometry in the mixture; (ii) crystallizing the zeolitic material from the mixture obtained in (i) to obtain the crystallized zeolitic material in its mother liquor.

Abstract: A process for preparing a zeolitic material, comprising (i) preparing a mixture comprising the at least one silicon containing precursor compound from which the zeolitic framework is formed, at least one pore forming agent, and at least one polymer which has an essentially spheroidal geometry in the mixture; (ii) crystallizing the zeolitic material from the mixture obtained in (i) to obtain the crystallized zeolitic material in its mother liquor.